Finance

Novo Nordisk Cuts U.S. GLP-1 Prices by Up to 50% for 2027

Novo Nordisk will cut the U.S. list price of GLP-1 drugs by as much as 50% starting in 2027, lowering Wegovy, Ozempic and Rybelsus to $675 per month. The move aims to reduce out-of-pocket costs and expand patient access, signaling a shift in payer negotiations and competition.

📅 February 25, 2026
⏱️ 2 min read
Novo Nordisk Cuts U.S. GLP-1 Prices by Up to 50% for 2027

Key Takeaways

  • Novo Nordisk will cut U.S. GLP-1 list prices up to 50% beginning 2027, with the new price at $675/month.
  • Prior monthly price range was $1,027–$1,350.
  • The move puts pricing pressure on Eli Lilly and could reshape payer contracts and formulary decisions.
  • Vivtex partnership adds up to $2.1 billion in upfronts and milestones for next-generation oral GLP-1 therapies.
  • Medicare obesity-treatment coverage is planned later this year to reach about 15 million patients.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Novo Nordisk A/S Developer of Wegovy/Ozempic/Rybelsus; implementing 2027 price cuts
  • Eli Lilly and Company Rival GLP-1 competitor (Mounjaro/Tirzepatide) facing pricing pressure
  • Vivtex Partner for next-generation oral GLP-1 therapies; up to $2.1 billion in upfronts/milestones

MarketMoodz Analysis

For investors, the price cut could compress Novo Nordisk’s near-term pricing power and accelerate discounting and payer negotiations across the GLP-1 space. A sharper-than-expected shift in price-to-value could alter forecasts for growth and margins in the obesity and diabetes franchises.

Historically, GLP-1 drugs commanded premium pricing as uptake surged; a 50% list-price reduction represents a material shift with potential ripple effects on rivals, formulary strategies, and patient access. The Vivtex deal signals a broader push toward convenient, potentially lower-cost oral GLP-1 therapies as part of the competitive race.

What to watch next: official confirmation from Novo Nordisk, details on discount mechanics, payer response and formulary decisions, and how Lilly responds with pricing or pipeline moves. Also monitor any Medicare coverage developments for obesity treatments announced later this year.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial